ONCY News and Press, Oncolytics Biotech Inc. From 04/11/24

2024-04-11 10:00:56 ET More on Oncolytics Biotech Oncolytics Biotech, Inc. (ONCY) Q4 2023 Earnings Call Transcript Seeking Alpha’s Quant Rating on Oncolytics Biotech Historical earnings data for Oncolytics Biotech Financial information for Oncolytics B...

2024-04-11 09:15:34 ET FN Media Group Presents USA News Group News Commentary Vancouver, BC – April 11, 2024 – USA News Group – The American Cancer Society is projecting 2024 to be the first year ever for the US to have more than 2 mill...

Oncolytics Biotech® Advances Toward Registration-Enabling Trial for Pelareorep in Breast Cancer with Submission of Type C Meeting Request to FDA Canada NewsWire Requested for Q2 2024, the Type C meeting is to focus on planned registration-enabling trial in HR+/HER2- metas...

USA News Group – Known as one of the most deadly forms of cancer, pancreatic cancer still has the highest mortality rate of all major cancers today. However, researchers and the biotech sector are working diligently to improve the chances of those who receive this dire diagnosis. Rec...

2024-03-14 08:45:28 ET FN Media Group Presents USA News Group News Commentary Vancouver, BC – March 14, 2024 – USA News Group – Known as one of the most deadly forms of cancer, pancreatic cancer still has the highest mortality rate of all m...

2024-03-09 01:09:07 ET Oncolytics Biotech, Inc. (ONCY) Q4 2023 Earnings Conference Call March 7, 2024, 4:30 pm ET Company Participants Jon Patton - Director, IR & Communications Matt Coffey - CEO Kirk Look - CFO Tom Heineman - CMO Allison Hagerman - V...

2024-03-07 16:39:40 ET More on Oncolytics Biotech Oncolytics Biotech: Numerous Early Readouts, But Dwindling Reserves Seeking Alpha’s Quant Rating on Oncolytics Biotech Historical earnings data for Oncolytics Biotech Financial information for Oncolytic...

Oncolytics Biotech® Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights Canada NewsWire Pelareorep advancing to a registration-enabling study in 2024 in pancreatic cancer and expands pancreatic potential with new GOBLET cohort in combina...

Gevo Inc. (GEVO) is expected to report $-0.05 for Q4 2023 Harvard Bioscience Inc. (HBIO) is expected to report $0.03 for Q4 2023 QuantaSing Group Limited (QSG) is expected to report $0.11 for Q2 2024 DFI Retail Group Holdings Limited ADR (DFIHY) is expected to report for quarter end 2...

2024-03-06 09:10:00 ET March 6, 2024 Investorideas.com , a global investor news source covering biotech and pharma stocks issues a sector snapshot on developments for pancreatic cancer treatments, featuring Oncolytics Biotech Inc. ( NASDAQ: ONCY ) (TSX: ONC ), a clinical-stage i...